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DNA priming has previously been shown to elicit augmented immune responses when administered by
electroporation (EP) or codelivered with a plasmid encoding interleukin-12 (pIL-12). We hypothesized that the
efficacy of a DNA prime and recombinant adenovirus 5 boost vaccination regimen (DNA/rAd5) would be
improved when incorporating these vaccination strategies into the DNA priming phase, as determined by
pathogenic simian immunodeficiency virus SIVmac239 challenge outcome. The whole SIVmac239 proteome
was delivered in 5 separate DNA plasmids (pDNA-SIV) by EP with or without pIL-12, followed by boosting 4
months later with corresponding rAd5-SIV vaccine vectors. Remarkably, after repeated low-dose SIVmac239
mucosal challenge, we demonstrate 2.6 and 4.4 log reductions of the median SIV peak and set point viral loads
in rhesus macaques (RMs) that received pDNA-SIV by EP with pIL-12 compared to the median peak and set
point viral loads in mock-immunized controls (P < 0.01). In 5 out of 6 infected RMs, strong suppression of
viremia was observed, with intermittent “blips” in virus replication. In 2 RMs, we could not detect the presence
of SIV RNA in tissue and lymph nodes, even after 13 viral challenges. RMs immunized without pIL-12
demonstrated a typical maximum of 1.5 log reduction in virus load. There was no significant difference in the
overall magnitude of SIV-specific antibodies or CD8 T-cell responses between groups; however, pDNA delivery
by EP with pIL-12 induced a greater magnitude of SIV-specific CD4 T cells that produced multiple cytokines.
This vaccine strategy is relevant for existing vaccine candidates entering clinical evaluation, and this model
may provide insights into control of retrovirus replication.
The human immunodeficiency virus (HIV) epidemic is a
major health problem, with more than 7,400 people infected
every day, the majority of whom live in sub-Saharan Africa
(56). Despite advances in HIV antiretroviral treatment and
efforts to increase access, it remains the case that just 36% of
HIV-infected people are receiving medication (58). Recent
advances in the use of preexposure prophylaxis and microbi-
cides, the implementation of policies for male circumcision,
and education in the use of condoms in sub-Saharan Africa are
promising approaches to slow infection rates (18, 29); how-
ever, an HIV vaccine offers the most sustainable, affordable,
and practical solution for controlling the HIV epidemic
worldwide.
Only a few of the HIV vaccine candidates currently in clin-
ical evaluation or under consideration for clinical development
have demonstrated a significant and sustained impact on virus
replication using analogous simian immunodeficiency virus (SIV)
vaccines in a stringent nonhuman primate (NHP) challenge
study (22, 34). Notably, a replicating rhesus cytomegalovirus
(rhCMV) vector expressing the full SIV proteome recently
demonstrated suppression of acute-phase virus replication and
seemingly prevented the acquisition of infection in over half of
the vaccinated rhesus macaques (RMs) following repeated
low-dose challenge with the highly pathogenic simian immu-
nodeficiency virus SIVmac239 (21, 22). Heterologous prime
and boost vaccination of RMs with recombinant adenovirus
(rAd) of serotype 26-Gag and rAd5-Gag decreased virus loads
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by 1.4 and 2.4 log at peak and set point, respectively, following
a single intravenous challenge with SIVmac251 (34). Both the
rhCMV and rAd26/rAd5 regimens were characterized by
broad, robust, antigen-specific multifunctional CD4 and CD8
T-cell responses that effectively influenced early events in virus
dissemination. These results indicate that vaccination can
elicit sustained suppression of viral replication and reem-
phasize the potential importance of T-cell immunity, partic-
ularly in the wake of the unsuccessful Merck rAd5-HIV
phase II trial (8, 13).
To date, vaccination of RMs with plasmid DNA (pDNA)
followed by a boost with replication-defective rAd5 expressing
SIV proteins has demonstrated limited efficacy following ho-
mologous SIV challenge, with a maximum reduction in viral set
point of 1.5 log consistently observed (4, 7, 33, 62). DNA-based
immunization strategies are attractive, particularly for HIV
vaccines, because of ease of manufacture, quality control,
safety, and stability for cold-chain delivery in developing coun-
tries. DNA-based vaccine approaches also avoid preexisting
antivector immunity that is problematic for viral vector-based
candidates that are in the HIV vaccine pipeline (13). The
efficacy of pDNA/rAd5 vaccination has not been examined in
an NHP SIV challenge protection study when using techniques
that enhance the immunogenicity of pDNA priming. Immuno-
genicity has been improved by optimization of coding regions
and the use of more efficient promoters to increase protein
expression (43, 49), coexpression of cytokine or chemokine
adjuvants, and the use of delivery methods that increase DNA
uptake (5, 9, 16, 50). For example, electroporation (EP) com-
bines an intramuscular (i.m.) DNA injection and simultaneous
administration of short electrical pulses (37, 46, 47, 51, 66).
Antigen presentation is improved by local inflammation and
recruitment of antigen-presenting cells (APCs) (19, 20, 59),
and protein production is increased, driven by more efficient
uptake and expression of DNA (59). Additionally, plasmid-
encoded interleukin-12 (pIL-12) has proven to be a promising
candidate adjuvant that enhances cellular and humoral re-
sponses (53, 64). Combining DNA delivery by EP with pIL-12
further enhanced immune responses in RMs (24) and is cur-
rently undergoing phase I clinical assessment (http://clinicaltri-
als.gov/ct2/show/NCT00991354?termpennvax&rank4).
Here, we present data from an SIV challenge protection
study, where we used a novel prime and boost combination to
enhance the immunogenicity of vaccination. We proposed that
codelivery of pDNA-SIV by EP with pIL-12 would augment
the T-cell response and, therefore, increase the efficacy of
DNA/rAd5-SIV vaccination. Strikingly, RMs that received a
pDNA-SIV prime coadministered with pIL-12 by EP demon-
strated greater than 2 and 4 log reductions in group median
peak and set point virus loads compared to the median peak
and set point loads in vaccine-naïve controls following re-
peated low-dose challenge with pathogenic SIVmac239. This
level of viral control is unprecedented for the DNA/rAd5
prime-boost strategy and was not observed in RMs that re-
ceived pDNA-SIV by EP without pIL-12.
MATERIALS AND METHODS
Vaccine construction. Plasmid DNA. The vaccine immunogens used in this
study covered the full SIVmac239 (GenBank accession number M33262) ge-
nome. Open reading frame nucleotide sequences were optimized for high ex-
pression in mammalian cells and cloned into an expression vector (32). The SIV
constructs were placed under the control of the human CMV promoter and the
bovine growth hormone polyadenylation signal (51). Gag (12S), Pol (91S), Env
(99S), and Nef (pCMV-Nef) were expressed as single proteins, while Vif, Vpr,
Vpx, Tat, and Rev were expressed as a fusion protein (pCMV-VVVTR) (21).
The Gag plasmid expressed a myristoylated Gag protein spanning amino acids 1
to 508, lacked 2 C-terminal amino acids, and was otherwise similar to a reported
Gag plasmid (49). The Env plasmid expressed a native form of gp160, as previ-
ously reported (32, 49). A plasmid containing a gene encoding sequence-opti-
mized Nef lacking a myristoylation signal was prepared with an insert amplified
from the 179S plasmid (32). Deletions were introduced into Pol to inactivate
protease (25DTG27), reverse transcriptase (184YMDD187), RNaseH (E478),
and integrase (D64, D116, and E152). Large-scale plasmid production for
DNA vaccine material was prepared by Aldevron LLC (Fargo, ND). The two
subunits of rhesus IL-12 (plasmid AG157) were expressed from a dual promoter
plasmid containing transcription units controlled by the human CMV immediate
early promoter (hCMV) and bovine growth hormone polyadenylation signal and
the simian CMV promoter (siCMV) and simian virus 40 (SV40) polyadenylation
signal (R. Jalah, B. Felber, and G. Pavlakis, unpublished data).
Recombinant Ad5 vectors. The same optimized SIVmac239 sequences used
for DNA-SIV plasmids were used to construct rAd5 vectors. The rAd5 vectors
were constructed in a E1A, partial E1B, and E3 genetic background using
the AdEasy adenoviral vector system (Stratagene, La Jolla, CA). SIVmac239
genes were cloned into the E1 region of the rAd5 vector under the control of the
hCMV immediate-early promoter-enhancer and the SV40 stop-polyadenylation
signal. Ad5-Null was used as a negative-control vector and had an identical
backbone but no transgene. All vectors were rescued in HEK 293 cells and
purified by double cesium chloride centrifugation (52). Dosing was based on
particle units (PU), determined by spectrophotometry (41). Large-scale rAd5
vector production was performed in HEK 293 cells by Puresyn, Inc. (Malvern,
PA). Immunogen expression was verified by Western blotting from plasmids
after transient transfection of HEK 293 cells or from rAd5 vectors after infection
of A549 cells, using polyclonal antibodies against SIVmac239 Gag, Env, Nef, and
Rev proteins prepared in rabbits and anti-SIVmac251 serum from the AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID, NIH.
Study cohort, vaccination, and SIV challenges. SIV-negative Indian RMs
(Macaca mulatta) were housed at the University of Pittsburgh in accordance with
the guidelines of the Association for Assessment and Accreditation of Labora-
tory Animal Care and with the approval of the University of Pittsburgh’s Insti-
tutional Animal Care and Use Committee (IACUC) standards/regulations. The
protocols were approved and assigned the IACUC number 0803208. Animals
were typed for major histocompatibility complex (MHC) type I alleles that
have been associated with preferential control of SIV infection, namely,
Mamu-A*01, -A*02, -A*11, -B*01, -B*03, -B*08, -B*17, and -B*29, for vac-
cine group allocation as previously described (28, 35, 65). No RMs positive
for Mamu-B*17 were included in the study. Animals were also typed for
TRIM5 allele genotypes TRIM5Q, TRIM5CYP, and TRIMTFP, as combina-
tions of these alleles have been associated with innate control of SIVsmE543
and E660 replication through binding of the capsid protein and inhibition of
unfolding of the virus (31, 44, 48).
RMs were divided into 3 groups (n  8 per group) equally distributed by age
and MHC class I allele expression. At weeks 0, 8, and 16, pDNA encoding the
whole SIVmac239 genome (gag, pol, nef, a vif-vpx-vpr-rev-tat fusion gene, and
env) was administered by EP (Inovio, United States) or by EP plus 0.1 mg of
rhesus pIL-12 at each vaccination site (0.4 mg pIL-12 in total). Constructs
encoding gag, pol, and env were delivered into separate limbs, and the nef gene
and VVVTR fusion gene were delivered into the same limb for a total of 4
vaccination sites per time point. The same receiving limb was used for each gene
construct for pDNA and rAd5 vaccinations, with pIL-12 codelivered with each
pDNA vaccination for the “with pIL-12” group. A negative-control group re-
ceived saline by EP. At week 33, all animals were boosted with 2  1010 virus
particles of rAd5 (rAd5-SIV) encoding all SIVmac239 genes. Negative controls
received an Ad5-Null vector.
We used a repeated low-dose viral challenge regimen of SIVmac239 to assess
vaccine efficacy (39). All animals were challenged intrarectally with a viral and
saline inoculum of 800 50% tissue culture infective doses (TCID50) of SIV-
mac239 (stock kindly supplied by D. Watkins, University of Wisconsin) every 2
weeks until infected. Blood was taken 1 week after each challenge, and Gag p27
in plasma measured by quantitative reverse transcription-PCR (qRT-PCR) to
determine productive infection. The peak viral load was defined as the highest
number of copies/ml detected within the first 3 weeks of infection. The set point
viral load was defined as the mean viral load from 1 week after peak out to 40
weeks postinfection.
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Sample collection. Peripheral blood was collected in sodium heparin tubes
(BD Biosciences, United States), and peripheral blood mononuclear cells
(PBMCs) isolated by density centrifugation on Ficoll (BioWhittaker, United
States) using Accuspin tubes (Sigma, United States). Cells were frozen and
stored in gaseous-phase liquid nitrogen. Blood was taken using SST tubes (BD
Biosciences, United States) and stored overnight at 4°C for serum collection.
Serum was heat inactivated for 35 min at 56°C and stored at 20°C. Inguinal or
auxiliary lymph nodes were surgically removed, and cell suspensions were ob-
tained by mechanical disruption of the tissue as previously described (25) and
immediately used for detection of SIV. To obtain plasma, whole blood was
collected in EDTA (BD, United Kingdom) tubes and centrifuged at 2,400 RPM
for 10 min.
Peptides. Fifteen-mer peptides (Anaspec, United States) spanning the entire
SIVmac239 proteome and overlapping by 11 amino acids were distributed into
10 open reading frame pools containing 50 to 125 peptides each. Peptides were
used at 2 g/ml in immunological assays. Staphylococcus enterotoxin B (SEB)
was used as a positive control (1 g/ml). The mock negative control consisted of
0.02% dimethyl sulfoxide to match peptide pools.
Intracellular cytokine staining. Between 600,000 and 1,000,000 PBMCs were
incubated with SIVmac239 peptide pools or control peptides (see “Peptides”) for
9 h with brefeldin A (Sigma, United States), CD49d, and CD28 (BD Biosciences,
United States) at 37°C with 5% CO2. Cells were washed and stained with
Live/Dead aqua viability fixable cell stain (Invitrogen, United States) and then
washed and stained for extracellular markers with CD3-Pacific Blue, CD4-peri-
dinin chlorophyll (PerCP) Cy5.5, and CD95-APC (BD Biosciences, United
States). Cells were permeabilized with Fix Perm and stained for markers and
intracellular cytokines with CD69-Texas Red, CD8-APC-H7, IL-2–phycoerythrin
(PE), gamma interferon (IFN-)–Alexa Fluor 700, and tumor necrosis factor
alpha (TNF-)–PE-Cy7 (BD Biosciences, United States). Events were collected
on an LSR-II (BD Biosciences, United States) and analyzed using FlowJo (Tree-
star, United States), Pestle, and SPICE (provided by M. Roederer, Vaccine
Research Center, NIAID, NIH). All data shown have had the mock-stimulated
background responses subtracted.
Binding-antibody enzyme-linked immunosorbent assay (ELISA). Serial dilu-
tions of heat-inactivated sera were incubated for 1 h on 96-well plates previously
coated with SIV Gag p55 protein (Protein Sciences Corp, United States) or SIV
Env gp130 (IAVI Neutralizing Antibody Consortium Repository, United States)
and then blocked for 1 h with 3% bovine serum albumin (BSA)–phosphate-
buffered saline (PBS). Plates were washed in 0.05% PBS–Tween and incubated
for 1 h with alkaline phosphatase-conjugated secondary antibody. After washing,
plates were incubated for 30 min with nitrophenylphosphate and optical density
measured at 450 nm using SoftMAx Pro GxP version 5 (Molecular Devices,
United States). All data shown have had the “no-serum” background subtracted.
qRT-PCR. One milliliter of plasma was spiked with 3.3 l of 3  104 copies/l
of Armored RNA enterovirus (Asuragen, Austin, TX) and pelleted by centrif-
ugation at 25,000  g for 1 h at 5°C. All liquid was removed, and total RNA
extraction was performed as described in the RNeasy minikit instructions (Qia-
gen, Valencia, CA). RNA was eluted in 50 l of RNase-free water, and real-time
qRT-PCR was performed as previously described (25) with the following mod-
ifications. Duplicate reaction mixtures per sample were prepared, and synthesis
of cDNA was performed using reagents from the Sensiscript reverse transcrip-
tase kit (Qiagen, Valencia, CA). Briefly, to detect Gag p27 genomic RNA, a
20-l reaction mixture was made containing 10 l of total RNA, 400 nM Gag p27
reverse primer 5CACTAGKTGTCTCTGCACTATPTGTTT3, 2 l of 10
reverse transcription buffer, 500 M each deoxynucleoside triphosphate (dNTP),
and 10 U of RNase inhibitor per l (all reagents from Qiagen’s Sensiscript RT
kit). The reaction mixture was reversed transcribed at 50°C for 45 min, followed
by heat inactivation of the reverse transcriptase at 95°C for 5 min. The real-time
quantitative PCR was carried out using a QuantiTect multiplex PCR kit
(Qiagen). A 30-l reaction mixture was made with 25 l of 2 QuantiTect multiplex
PCR master mix, 400 nM (each) forward primer 5GTCTGCGTCATPTGGTG
CAT3 and reverse primer plus 200 nM 6-carboxyfluorescein (FAM)-labeled
minor groove binder (MGB) probe specific for Gag p27 (5-6FAM-CTTCPTC
AGTKTGTTTCA-MGB-3). This mixture was combined with the 20-l cDNA
mixture, and amplification and detection were performed with a Stratagene
Mx3005P sequence detection system (La Jolla, CA) using the following condi-
tions: 15 min at 95°C to activate the Hot Star Taq DNA polymerase, followed by
45 cycles of 15 s at 94°C and 60 s at 60°C. Copy numbers for test samples were
determined by interpolation onto a standard curve of RNA standards.
Statistical analysis. Log rank tests were used to determine whether vaccina-
tion had an effect on infection rate. Nonparametric tests were performed to
detect statistical differences between vaccine groups due to the small sample
sizes. Kruskal-Wallis one-way analysis of variance (ANOVA) was used to com-
pare all 3 groups. Wilcoxon rank sum tests were performed to determine signif-
icant differences between the median values of group pairs, using an adjusted P
value cutoff of 	0.0167 for multiple comparisons. Peak viral load was defined as
the highest viral load measured in the first 3 weeks of infection. Set point viral
loads were defined using values from the first time point after peak viral load out
to a maximum of 40 weeks postinfection. Uninfected animals were assigned viral
load values of 0 for these analyses.
RESULTS
EP DNA codelivered with pIL-12 DNA and boosted with
rAd5 elicits significant control of virus replication. To assess
whether vaccination efficacy was improved if the immunoge-
nicity of the DNA priming component was enhanced, we de-
livered the whole SIVmac239 genome in 5 separate pDNA-
SIV plasmids (Gag, Pol, Env, Nef, and Vif/Vpr/Vpx/Tat/Rev
fusion) in 3 successive primes delivered by EP with or without
pIL-12 (at weeks 0, 8, and 16). The animals were boosted 4
months later with 5 corresponding separate rAd5-SIV con-
structs. Thus, the 24 RMs (n  8 per group) were primed with
pDNA-SIV, pDNA-SIV with pIL-12, or mock vaccination. We
challenged the RMs repeatedly with the highly pathogenic
virus clone SIVmac239 until they became infected or reached
a maximum of 13 low-dose intrarectal challenges administered
per animal (Fig. 1A). The RMs that received mock challenge
or pDNA-SIV without pIL-12 immunization all became in-
fected after 7 challenges (medians of 4 and 5, respectively)
(Fig. 1B). In RMs that received pDNA-SIV codelivered with
pIL-12, 6 became infected following a maximum of 9 chal-
lenges (median of 3), and the other 2 remained uninfected
after all 13 challenges (Fig. 1B). We could not detect SIV RNA
in the tissue or lymph nodes of the 2 uninfected RMs after all
13 challenges (data not shown). As expected due to the small
sample sizes, we did not observe a difference between vaccine
groups in the number of challenges required to acquire infec-
tion (Fig. 1B) (P 
 0.05) (26, 27).
We did not detect any factor that could implicate an effect
on infection or virus load between groups other than the vac-
cine administered. The number of challenges required to infect
each of the RMs in the study did not affect the kinetics of
infection or viral load (Fig. 1C). The presence of MHC class I
allele Mamu-B*17 or -B*08 in RMs infected with SIV has been
correlated with a reduction in plasma viremia (35, 36, 45, 65),
as seen in humans infected with HIV type 1 (HIV-1) who
express HLA-B*57 (17). In this study, we excluded animals
that expressed Mamu-B*17, but each of the immunization and
control groups included a single RM that expressed Mamu-
B*08 (Fig. 1C). As expected, the Mamu-B*08-expressing RM
in the mock-vaccinated group (RM-474) demonstrated a low
virus load compared to the virus loads in the remainder of the
unimmunized population (Fig. 1C). The effect of Mamu-B*08
was enhanced upon immunization with pDNA-SIV with or
without pIL-12; RMs positive for this genotype (RM-614 and
RM-622) controlled virus replication by 
3 log following peak
viremia (Fig. 1C). Furthermore, we did not observe an associ-
ation between MHC class I allele Mamu-A*01 and lower virus
loads as previously suggested (42); however, enhanced sup-
pression of virus replication was observed in Mamu-A*01-
positive RMs that coexpressed Mamu-B*08 or were immu-
nized with pDNA-SIV with pIL-12 (Fig. 1C).
To determine the efficacy of each vaccination regimen, we
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FIG. 1. (A) Study design. Numbers on time line indicate the vaccination time points and the first challenge, in weeks. See Materials and
Methods for details. (B) Number of low-dose SIVmac239 intrarectal challenges required to infect rhesus macaques in each immunization group
when the DNA prime components in the prime-boost regimen differ. (C) Kinetics of SIVmac239 infection from 0 to 40 weeks in each rhesus
macaque. The animal identification number on each graph is followed by the MHC-I haplotype in parentheses. The number of challenges that
occurred before virus was detectable in plasma is indicated above the graph for each immunization group. Dotted horizontal lines indicate group
median set point viral loads. EP, electroporation delivery of pDNA-SIV; pIL-12, plasmid encoding IL-12; rAd5, recombinant Ad5-SIV boost.
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compared control of SIVmac239 replication at peak and set
point viral loads. RMs that received pDNA-SIV alone (without
pIL-12) and rAd5-SIV boost had modestly reduced group me-
dian plasma genome copy numbers (of approximately 1 log) at
the peak and set point viral loads compared to the copy num-
bers in naïve controls (Fig. 2), which was a result similar to the
results seen in previous work with conventional i.m. needle
injection of pDNA/rAd5-SIV prime-boost followed by high-
dose (7, 54) or low-dose (62) intrarectal pathogenic SIV chal-
lenge (Fig. 2). Coadministration of pDNA-SIV with pIL-12
significantly improved vaccination efficacy, with further reduc-
tions of median peak and set point viral loads by 1.5 log and 4
log, respectively, compared to the results for immunization in
the absence of pIL-12. Strikingly, RMs vaccinated with pDNA-
SIV with pIL-12 had median viral loads that were reduced by
more than 2.6 log at peak and 4.4 log at set point compared
with the results in mock-immunized controls (P  0.0013 at
peak, P  0.0027 at set point) (Fig. 2B and C). This level of
control of SIV replication is unprecedented compared to the
results in other studies following either homologous or heter-
ologous prime-boost vaccination with pDNA delivered intra-
muscularly and replication-defective rAd5 in a high-dose (4, 7,
54) or low-dose challenge (61, 62), and is comparable to the
control of viremia recently observed following immunization
with whole SIVmac239 genes vectored by replication-compe-
tent rhCMV (22). Given that all RMs received the same SIV
genes delivered by EP and rAd5 boost, this result strongly
implicates a critical role for the expression of IL-12 during the
priming phase when generating an immune response capable
of exerting sustained control of SIV replication.
We retrospectively examined the TRIM5 genotype of all
RMs, as polymorphisms at this locus can influence innate con-
trol of infection and replication as described for SIVsmE543
and E660 (44, 48). Briefly, there are 3 functional TRIM alleles
that act by binding to capsid protein: TRIM Q, TFP, and cy-
clophilin A (Cyp). Combinations of these functional genotypes
in RMs differentially influence uncoating of the virus during
cell entry by binding to capsid protein, with TRIM TFP/Cyp
genotypes inhibiting SIV infection to a greater extent than
TRIM Q/Q, Q/Cyp, Q/TFP, or TFP/TFP. After evaluation of
the genotypes, we confirmed that there was no association
of TRIM5 polymorphism with virus load or the number of
exposures required to infect the individual RMs (Fig. 3)
(31).
DNA priming by EP with pIL-12 preferentially affects T-cell
responses. We examined both antibody and T-cell responses in
RMs. Serum was analyzed by ELISA for SIV-specific binding
IgG antibodies (Ab) directed against SIV Env gp130 and Gag
p55 proteins. Gag- and Env-specific antibodies that were
boosted in magnitude by rAd5 were detected in both immuni-
zation groups after pDNA-SIV priming (Fig. 4). Historically,
coadministration of pIL-12 with pDNA has induced a higher
FIG. 2. (A) Longitudinal virus load of each immunization group.
(B and C) Peak (B) and set point (C) virus load of each immunization
group. Gag p27 RNA in plasma was detected by RT-PCR. Group
median viral loads are indicated by a solid horizontal black line in each
box-and-whisker plot. Error bars show standard deviations. pIL-12,
plasmid encoding IL-12; rAd5, recombinant adenovirus 5-SIV boost.
FIG. 3. Analysis of the acquisition and kinetics of infection in rhesus macaques, grouped by TRIM5 polymorphisms. (A) Number of low-dose
intrarectal challenges required for infection with SIVmac239. (B) Mean viral loads over time as measured by RT-PCR. Error bars show standard
deviations.
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magnitude of IgG Ab responses than pDNA alone; however,
we did not observe any difference here (Fig. 4). EP delivery of
pDNA-SIV with or without pIL-12 elicited cytokine-producing
CD4 and CD8 T-cell responses to each of the SIVmac239
vaccine immunogens (Fig. 5). This is consistent with data from
other EP studies in NHPs and clinical assessment (30, 37, 50).
Interestingly, rAd5-SIV preferentially boosted CD8 T-cell re-
sponses in both immunization groups with little or no boosting
observed in the CD4 T-cell compartment, except for Gag re-
sponses (Fig. 5). pDNA-SIV priming with pIL-12 elicited a
greater frequency of Gag-specific CD4 T cells and significantly
more Env-, Nef-, and Pol-specific CD4 T cells than were seen
in RMs that received pDNA-SIV alone (Fig. 5). EP of pDNA-
SIV elicited overall a high frequency of multifunctional anti-
gen-specific CD8 and CD4 T cells (Fig. 6). Notably, the fre-
quency of multifunctional SIV-specific CD4 T cells was
significantly higher in RMs that received pDNA-SIV and pIL-
12, but these populations were not boosted in frequency fol-
lowing rAd5-SIV vaccination (Fig. 6).
DISCUSSION
The primary objective of this study was to determine
whether codelivery of a plasmid expressing IL-12 with pDNA-
SIV would increase DNA/rAd5 prime-boost vaccination effi-
cacy, as assessed in a stringent NHP SIVmac239 challenge
protection study. We demonstrate that 5 of 6 RMs that re-
ceived pDNA-SIV priming vaccinations with pIL-12 controlled
SIVmac239 replication to undetectable levels. Additionally,
these RMs had a peak level of SIV replication that was re-
duced by almost 3 log and a set point virus load that was lower
by approximately 4.5 log than the peak and set point virus
loads in mock-immunized controls. Moreover, there was a 4
log difference in vaccine efficacy (as evidenced by median set
point viral load) between this group and RMs primed with
pDNA-SIV without pIL-12. To our knowledge, we are the first
to prime conventional replication-deficient rAd5-SIV with
pDNA-SIV codelivered by EP with pIL-12, and we show a
significant improvement in vaccine efficacy. Although rAd5 is
unlikely to be advanced into large-scale clinical trials due to
preexisting immunity to the vector (40), this proof-of-concept
study demonstrated that the efficacy of the pDNA prime vector
boost vaccination platform was significantly increased when
techniques previously shown to improve the immunogenicity of
pDNA immunization were employed.
The kinetics and levels of virus control observed in this
study, characterized by virus suppression immediately after
infection and sustained undetectable virus loads with intermit-
tent blips of replication, were similar to those detected
in RMs immunized with live attenuated viruses, such as
SIVmac239Nef or rhCMV (10, 22). Control of viral replica-
tion and potential protection from infection in the rhCMV
vaccine model was associated with the induction of long-lived
SIV-specific T cells with an effector memory phenotype (22) in
the absence of neutralizing antibodies. Further analyses are
planned to determine whether the presence of IL-12 modu-
lated the phenotype of SIV-specific T cells induced in this
study upon DNA priming, as well as functional antibody assays.
Additionally, in both studies, RMs were immunized with each
gene from the SIVmac239 genome, which may be advanta-
geous in eliciting broad T-cell responses that exert immune
pressure upon early virus replication, leading to sustained viral
control. While other DNA/rAd vaccine regimens with various
combinations of SIV genes have demonstrated limited efficacy
following high-dose (4, 7, 38, 54) or low-dose (61, 62) chal-
lenge, this regimen has not previously shown control of early
virus replication to the same extent as observed here, impli-
cating an important role for IL-12.
The present study was not designed to determine whether
vaccination reduced the frequency of infection, as many more
animals are required to determine statistically significant pro-
tection (26, 27). Nevertheless, 2 RMs immunized with pDNA-
SIV with pIL-12 at priming vaccination had no detectable virus
loads following multiple exposures to pathogenic SIVmac239.
Indeed, no SIV could be detected in lymph node tissues of
these 2 RMs, indicating that they either cleared the virus or
were refractory to SIV infection. We explored whether there
could be genotypic differences between vaccinated and mock-
vaccinated RMs to which viral control could be attributed.
TRIM5 polymorphisms have been associated with failure of
FIG. 4. Mean binding antibody titers specific for SIV Env gp130
(A) and SIV Gag p55 (B) postvaccination and -infection in each
immunization group. Dotted vertical lines indicate infectious chal-
lenge. Mean titers are shown for infected animals only postinfec-
tion. Error bars show standard errors of the means. *, P 	 0.05; **,
P 	 0.01; pIL-12, plasmid encoding IL-12; rAd5, recombinant ad-
enovirus 5-SIV boost; ND, not done.
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SIV to infect RMs expressing particular TRIM5 variants that
bind to virus capsid and prevent uncoating with certain virus
isolates (48, 44). Here, we analyzed TRIM5 alleles in our
cohort and found that there was no association with TRIM5
and resistance to SIVmac239 infection, specifically in the 2
RMs that remained uninfected. This confirms the in vitro find-
ing that TRIM5 variants do not bind efficiently to SIVmac239
capsid, due to amino acid substitutions in the capsid of the
cloned virus (31).
We also examined the MHC genotypes of RMs to determine
whether this influenced viral control in vaccinated animals.
Control of SIV, like HIV, has been shown to be associated with
the expression of particular MHC class I alleles, such as
Mamu-B*17 and -B*08 and, to a lesser extent, Mamu-A*01 in
Indian RMs (35, 36, 42, 65). While this effect on virus replica-
tion is not absolute (45, 63), we excluded RMs expressing the
class I allele Mamu-B*17 from this study cohort. Regardless of
TRIM5 or MHC class I genotype, the entire mock-immu-
nized study group became infected with typical peak virus
loads for SIVmac239 following a median of 4 challenges. As
expected, a single Mamu-B*08 RM had a 2 log reduction in
virus load by 15 weeks postinfection. The remaining 7 RMs
(including one expressing Mamu-A*01) failed to suppress virus
replication at peak or set point. In RMs expressing the pro-
tective MHC class I molecule Mamu-B*08 that received
pDNA-SIV with or without pIL-12, we observed early suppres-
sion of SIV compared to the results in the mock-immunized
controls. Data from the Merck phase I STEP trial demon-
strated that vaccinated individuals that expressed HLA-B*27,
-B*57, or -B*58 had significantly lower virus loads following
infection than vaccinated individuals that expressed HLA al-
leles not associated with virus control (14). The results pre-
sented here also indicate that vaccination can enhance the
capability of antigen-specific CD8 T-cell responses restricted
by “protective” MHC class I alleles to recognize infected cells.
Additional studies using large cohorts of NHPs lacking any
alleles associated with low virus loads are warranted to confirm
early control of virus replication following immunization with
pDNA-SIV with pIL-12 followed by rAd5. However, it is evi-
dent from the present study that the RMs lacking protective
MHC class I alleles controlled SIVmac239 replication follow-
ing EP SIV DNA plus pIL-12/rAd5 prime-boost, which sug-
gests that the control observed was not the consequence of a
fortuitous alignment of protective alleles in any particular vac-
cine group.
IL-12 is produced by activated dendritic cells (DCs) and
macrophages following recognition of pathogens, and it en-
hances the activation of T cells, B cells, and natural killer (NK)
cells (55, 57). It has been shown that the administration of
recombinant rhesus IL-12 to RMs followed promptly by
SIVmac251 challenge resulted in an enhanced immune re-
sponse to challenge infection, characterized by increased se-
rum IFN- and circulating SIV-specific CD8 and CD4 T cells
and reduced virus loads (1). Immunization of RMs with pIL-12
and SIV DNA that encoded SIV Gag, Env, and Pol resulted in
the reduction of SIVmac251 replication by 1.5 log (24). In a
less rigorous simian-human immunodeficiency virus (SHIV)-
89.6P challenge, there was a 2.4 log reduction in virus replica-
tion following the SIV DNA plus pIL-12 prime and vector
boost vaccination with vesicular stomatitis virus expressing SIV
FIG. 5. Frequency of SIV-specific CD8 (A) and CD4 (B) T cells producing any combination of IFN-, TNF-, or IL-2 on stimulation with SIV
peptide pools, as indicated on each graph, postvaccination and -challenge. Dotted vertical lines indicate infectious challenge. Mean percentages
are shown for infected animals only postinfection. Error bars show standard errors of the means. *, P 	 0.05; **, P 	 0.01; ***, P 	 0.001; V/V/V,
Vif/Vpr/Vpx; pIL-12, plasmid encoding IL-12; rAd5, recombinant adenovirus 5-SIV boost.
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Gag and HIV Env gp160 (12). In all these studies, viral control
was associated with an increased antibody and IFN- T-cell
response detected either by flow cytometry or enzyme-linked
immunosorbent spot assay (ELISPOT). In agreement with and
extending these earlier findings, we detected broad, multifunc-
tional IFN-, TNF-, or IL-2 CD4 and CD8 T-cell responses
directed against each SIV protein. The antigen-specific CD8
T-cell responses were more sustained following vaccination
codelivered with pIL-12. No difference in the magnitude of
binding SIV-specific Ab was observed between vaccine groups;
however, suppression of virus replication may have occurred in
these animals through direct neutralization or antibody-depen-
dent cell-mediated mechanisms, as has been described in
HIV-1 infection (15, 23, 60). Work is ongoing to examine the
neutralizing and nonneutralizing properties of SIV-specific Ab
induced with and without pIL-12. Further studies that include
a control group immunized with pIL-12 alone to examine non-
specific effects of IL-12 on control of virus replication are
needed to specify immune correlates of protection induced
upon the incorporation of IL-12 into vaccination.
One clear feature of DNA priming with pIL-12 was the
increased quantity and quality of SIV-specific CD4 T cells after
DNA prime. There were 3-fold more SIV-specific CD4 T cells
detected in the group receiving pDNA-SIV with pIL-12 than in
the group primed without pIL-12. Moreover, 50% of those
cells produced 3 cytokines, compared to less than 20% of the
SIV-specific CD4 cells induced in the other vaccine groups.
CD4 T cells can mediate cytolysis (2, 6), as well as provide
costimulatory signals to antigen-presenting cells for the activa-
tion and induction of effector and memory CD8 T-cell popu-
lations (3). It has been proposed that vaccines should avoid
stimulating HIV-/SIV-specific CD4 T cells because HIV spe-
cifically targets activated HIV-specific CD4 T cells, and induc-
tion of these cells through vaccination could potentially lead to
exacerbation of early infection (11). Our data demonstrate that
vaccine-elicited antigen-specific CD4 T cells may be advanta-
geous in maintaining immune control of virus replication.
This study adds to the developing evidence that control of
SIV/HIV replication is achievable by vaccination. While the
current study is underpowered to unequivocally demonstrate
an effect on the susceptibility of infection, we believe there is a
suggestion that vaccination can also reduce the rate of infec-
tion. Clearly, it would be highly desirable to achieve these
effects in humans with a vaccine. The current study suggests
several paths toward this goal. Further analysis of immune
responses in controlling animals using protective vaccination
FIG. 6. Mean frequencies of SIV-specific CD8 (A) and CD4 (B) T cells producing 1, 2, or 3 cytokines (IFN-, TNF-, or IL-2) on stimulation
with SIV peptide pools spanning the whole proteome following SIV DNA priming and rAd5 boost. (C) Pie charts below the bar graphs indicate
the relative proportions of SIV-specific CD4 and CD8 T cells at each time point that produced each combination of cytokines. Error bars show
standard errors of the means. *, P 	 0.05; **, P 	 0.01; pIL-12, plasmid encoding IL-12; rAd5, recombinant adenovirus 5-SIV boost.
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protocols such as the one demonstrated here or using rhCMV
vectors should assist in the design of HIV vaccines that are
capable of potent virus control. Second, it should be possible to
adapt the vaccination approach shown here to human clinical
testing. With this in mind, we plan to determine whether a
vaccine encoding fewer proteins is equivalently effective and
whether the rAd5 boost can be replaced with a more clinically
relevant viral vector while maintaining efficacy.
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